{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Daniel Edward Horner, Sarah Davis, Abdullah Pandor, Helen Shulver, Steve Goodacre, Daniel Hind, Saleema Rex, Michael Gillett, Matthew Bursnall, Xavier Griffin, Mark Holland, Beverley Jane Hunt, Kerstin de Wit, Shan Bennett & Robin Pierce-Williams.

Daniel Edward Horner ^1,2,3,*, Sarah Davis ³, Abdullah Pandor ³, Helen Shulver ³, Steve Goodacre ³, Daniel Hind ³, Saleema Rex ³, Michael Gillett ³, Matthew Bursnall ³, Xavier Griffin ⁴, Mark Holland ⁵, Beverley Jane Hunt ⁶, Kerstin de Wit ^7,8, Shan Bennett ³, Robin Pierce-Williams ⁹

¹ Emergency Department, Northern Care Alliance NHS Foundation Trust, Salford, UK
² Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Oxford Road, Manchester, UK
³ School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
⁴ Barts Bone and Joint Health, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
⁵ School of Clinical and Biomedical Sciences, Faculty of Health and Wellbeing, University of Bolton, Bolton, UK
⁶ Thrombosis & Haemophilia Centre, St Thomas’ Hospital, King’s Healthcare Partners, London, UK
⁷ Department of Emergency Medicine, Queens University, Kingston, ON, Canada
⁸ Department of Medicine, McMaster University, Hamilton, ON, Canada
⁹ Thrombosis UK, Llanwrda, UK
^* Corresponding author Email: daniel.horner@srft.nhs.uk

Disclosure of interests

Full disclosure of interests: Completed ICMJE forms for all authors, including all related interests, are available in the toolkit on the NIHR Journals Library report publication page at https://doi.org/10.3310/AWTW6200.

Primary conflicts of interest: Steve Goodacre was Deputy Programme Director of the NIHR Health Technology Assessment (HTA) programme and chair of the NIHR HTA commissioning committee up to 31/12/2020, which included membership of the HTA Remit and Competitiveness Group, HTA Post-Funding Committee teleconference, HTA Funding Committee Policy Group and HTA Prioritisation Group. Daniel Hind is a current member of the NIHR HTA Clinical Evaluation and Trials Committee, and NIHR HTA Fast Track Committee. Mark Holland has received honorariums from Pfizer for conference presentations. Kerstin de Wit has received an unrestricted grant from Bayer. Dan Horner has previously acted as a paid subject matter expert on venous thromboembolic disease for the Healthcare Safety Investigation Branch. Beverley Hunt, Dan Horner and Xavier Griffin were previously involved in developing relevant National Institute for Health and Care Excellence (NICE) guidance on prevention and management of venous thromboembolic disease.